Chemotherapy-induced peripheral neurotoxicity assessment:

integrative review and implications for oncology nursing practice

Authors

  • Delma Aurélia da Silva Simão Hospital São João de Deus, Unidade de Quimioterapia. Divinópolis, MG – Brasil; Universidade Federal de Minas Gerais – UFMG, Escola de Enfermagem, Programa de Pós-Graduação. Belo Horizonte, MG – Brasil. Enfermeira especialista em Enfermagem Hospitalar Oncologia, Mestranda, Bolsista do Programa Capes/Reuni.
  • Elenice Dias Ribeiro de Paula Lima Universidade Federal de Minas Gerais – UFMG, Escola de Enfermagem, Núcleo de Estudos e Pesquisas em Cuidado e Desenvolvimento Humano. Belo Horizonte, MG – Brasil. Doutora em Research and Theory Development pela New York University, Professora adjunta.
  • Raíssa Silva Souza Universidade Federal de Minas Gerais – UFMG, Escola de Enfermagem, Programa de Pós-Graduação. Belo Horizonte, MG – Brasil. Enfermeira especialista em Enfermagem Hospitalar Terapia Intensiva, Mestranda, Bolsista do Programa Capes/Reuni.
  • Késsia Rubia Alves Hospital São João de Deus, Ambulatório de Quimioterapia. Divinópolis, MG – Brasil; Enfermeira. Especialista em Enfermagem Hospitalar – Oncologia.
  • Waléria Maria Maia Hospital São João de Deus, Unidade de Internação Oncológica. Divinópolis, MG – Brasil; Enfermeira. Especialista em Enfermagem Hospitalar – Oncologia.

DOI:

https://doi.org/10.5935/2316-9389.2012.v16.50285

Keywords:

Oncologic Nursing, Nursing Care, Drug Therapy, Paraesthesia

Abstract

Chemotherapy Induced Peripheral Neuropathy (CIPN) is a common toxicity result of using potentially neurotoxic antineoplastic agents. Its symptoms have an important impact on instrumental activities of daily living (IADLs) and, therefore, monitoring its symptoms is fundamental for the implementation of an effective nursing care. In order to raise and discuss the main methods used for monitoring CIPN and some aspects relevant to nurses' performance, an integrative literature review was carried out between November 2009 and August 2010. The following steps were followed: establishment of a sample selection criteria; registration of instruments assessed at the original research; data analysis; interpretation and presentation of results. The results demonstrated that doctors and nurses developed instruments that, with their advantages and/or limitations, were published in order to standardize assessments. Among them electroneuromyography is "gold standard" for assessing CIPN. Instruments such as FACT/GOG-Ntx, the PNQ and QANPIA are still being evaluated in different languages, populations and study designs. In conclusion there is still no agreement on the best way to assess the severity of the alterations, as there is no nursing protocol established for evaluation. The development of effective tools would enable a better assessment of neuropathy and the discovery of new interventions.

Downloads

Download data is not yet available.

References

1. Bonassa EMA, Santana TR. Enfermagem em terapêutica oncológica. 3ª ed. Rio de Janeiro (RJ): Atheneu; 2005. 538p.

2. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination

chemotherapy: Clinical and electrophysiological studies. Ann Neurol. 1994; 3(35): 304-11.

3. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Expert Opinion on Drug Safety. 2004; 6(3):535-46.

4. Velasco R, Bruna J. Chemotherapy-induced peripheral neuropathy: an unresolved issue. Neurol. 2010; 2(25): 116-31.

5. Mcwhinney SR, Goldberg RM, Mcleod H. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009; 1:8.

6. Ibrahim A. FDA drug approval summaries: oxaliplatin. Oncologist. 2004; 9:8-12.

7. Shimozuma K, Ohashi Y, Takeuchi A, et al. Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009; 17:1483-91.

8. Lima EDRP, Torres MQ, Bacelar MV, et al. Symptom Distress: validation of a measure in Brazil. In: 16th International Conference on Cancer Nursing, 2010, Atlanta. 16th International Conference on Cancer Nursing Abstract Book. Vancouver: Wiley-Blackwell; 2010. p.102.

9. Wampler MA, Rosenbaum EH. Chemotherapy-induced peripheral neuropathy fact sheet. Cancer Supportive Care Programs. 2008. [Citado 2010 jun. 27]. Disponível em: .

10. Almeida EM, Gutiérrez MGR., Adam NP. Monitoramento e avaliação dos efeitos colaterais da quimioterapia em pacientes com câncer de cólon. Rev Latinoam Enferm. 2004; 12(5).

11. North American Nursing Diagnosis Association. Diagnósticos de enfermagem da NANDA: definições e classificações 2007-2008. Porto

Alegre: Artes Médicas; 2007. 396 p.

12. Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nurs. 2007; 11(3):361-76.

13. Sweeney CW. Understanding peripheral neuropathy in patients with cancer: background and patient assessment. Clin J Oncol Nurs. 2002; 6:163-6.

14. Binner M. Chemotherapy-induced peripheral neuropathy: assessment of oncology nurses’ knowledge and practice. 2010. 16th International

Conference on Cancer Nursing. Abstract book. Vancouver: Wiley-Blackwell; 2010. p.120-1.

15. Markman M. Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life. J Cancer Res Clin Oncol. 1996; 122(9):511-2.

16. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). 2009. [Citado 2009 nov. 18]. Disponível em: http.//ctep. cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40>.

17. Clinical Trials Brazil. CTCAE - Common Terminology Criteria for Adverse Events. [Citado 2010 maio 30]. Disponível em:

clinicaltrialsbrazil.com/ctcae>.

18. Cavaletti G., Frigeni B., Lanzani F., Matavelli L., Susani E. Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of

the currently available tools. European Journal of Cancer. 2010 n. 4 6, p. 479-494.

19. Instituto Nacional do Câncer. Ações de enfermagem para o controle do câncer: uma proposta de integração ensino-serviço. 3. ed.atual. amp. – Rio de Janeiro: INCA, 2008. 488 p.

20. Beyea SC, Nicoll ELH. Writing an integrative review. Aorn J 1998 April, n. 67, v. 4, p. 877-878.

21. Pubmed. US National Library of Medicine. National Institutes of Health. Disponível em: http.//www.ncbi.nlm.nih.gov/pubmed/. Acesso em 20 de novembro de 2011.

22. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003; 30:5-13.

23. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin

Oncol. 2002; 20:1767-74.

24. Valério ABCO, Nobrega AM, Petertilberty C. Condução nervosa em nervos da mão e fator fisiológico idade. Arq Neuropsiquiatr. 2004;

62(1):114-8.

25. Marciano LHSC, Garbino JA. Comparação de técnicas de monitorização da neuropatia hanseniana: teste de sensibilidade e estudo de

condução nervosa. Hansen Int. 1994; 19(2): 05-10.

26. Cavaletti G, Frigeni B, Lanzani F, et al. The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-CommonToxicity Scale. J Perip Nerv S. 2007; 12:210-5.

27. Smith EML, Cohen JA, Pett MA, Beck SL. The reability and validity of modified Total Neuropathy Score – reduced and neuropathic paim

severity items when used to measure Chemotherapy-Induced Peripheral Neuropathy in pacients receiving taxanes and platinuns. Canc Nurs. 2010; 33(3):173-83.

28. Smith EML, Beck SL. The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum. 2008; 35(1):96-102.

29. Leonard GD, Wright M, Quinn M, Grem J. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005; 5(116):1-10.

30. Bakitas MA. Background noise: the experience of chemotherapy- induced peripheral neuropathy. Nurs Research. 2007; 56(5):323-31.

31. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effect of taxane therapy in oncology. Cancer. 2003; 98:822-31.

32. Mccloskey JC, Bulecheck GM, Nursing intervention Classification (NIC). 3ª ed. St. Louis: Mosby; 2004.

Downloads

Published

2012-12-01

Issue

Vol. 16 No. 4 (2012)

Section

Review

License

Copyright (c) 2012 Reme: Revista Mineira de Enfermagem

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

1.
Simão DA da S, Lima EDR de P, Souza RS, Alves KR, Maia WM. Chemotherapy-induced peripheral neurotoxicity assessment:: integrative review and implications for oncology nursing practice. REME Rev Min Enferm. [Internet]. 2012 Dec. 1 [cited 2026 Oct. 14];16(4). Available from: https://periodicos.ufmg.br/index.php/reme/article/view/50285

Most read articles by the same author(s)